keyboard_arrow_up

Global Inflammatory Bowel Disease Market to grow at a CAGR of 3.95 percent by 2019

Global Inflammatory Bowel Disease Market 2015-2019 is a new market research publication announced by Reportstack. Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management.  The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors.

The analysts forecast that the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.

To access full report with TOC, please visit  Global Inflammatory Bowel Disease Market 2015-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis.

On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments.

• 5-ASA
• Antibiotics
• Immunomodulators
On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.

• Biologics
• Small Molecules
On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments.
• Oral
• Parenteral

On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments.

• Solid
• Liquid
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Inflammatory Bowel Disease market. The vendor landscape includes an analysis of the major vendors, along with the competitive performances of their portfolios. In addition, the report discusses the major drivers, challenges and trends influencing the market. In addition, late-stage pipeline molecules developed for the treatment of inflammatory bowel disease are discussed.

The report, Global Inflammatory Bowel Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the landscape of the Global Inflammatory Bowel Disease market and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA    
   
Key Vendors
• Abbvie
• Biogen Idec
• Janssen Pharmaceuticals
• Merck & Company
• Shire
• UCB 

Other Prominent Vendors
 • Amgen
• Akebia Therapeutics
• Boehringer Ingelheim
• Celltrion
• ChemoCentryx
• Ferring Pharmaceuticals
• Galapagos
• Genentech
• Merck
• Mitsubishi Tanabe
• Novartis
• Novo Nordisk
• Pfizer
• Salix Pharmaceuticals

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###